Jubilant Ingrevia Limited has informed the Exchange that Board of Directors at its meeting held on May 13, 2025, recommended Final Dividend of 2.5 per equity share.
JUBLINGREA · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
On the reaction day the stock moved 2.9 pts less than Nifty Smallcap 250 and 2.8 pts less than its Specialty Chemicals peers, over the same two closes: a difference in percentage points, not a measure of what the filing did.
Minute windows have no benchmark: there is no intraday index history to compare against.
Jubilant Ingrevia's Board of Directors, at its meeting on May 13, 2025, approved audited financial results (standalone and consolidated) for Q4 and the financial year ended March 31, 2025, with the statutory auditor (Walker Chandiok & Co LLP) issuing an unmodified opinion. The Board recommended a final dividend of Rs. 2.50 per equity share (250% on Re. 1 face value), taking the total FY25 dividend to Rs. 5 per share (interim Rs. 2.50 + final Rs. 2.50), aggregating to Rs. 7,964 lakhs. Consolidated revenue rose modestly to Rs. 4,177.6 crore (vs Rs. 4,135.8 crore in FY24), but net profit jumped ~37% to Rs. 251.2 crore (vs Rs. 182.9 crore), driven by strong performance in the Specialty Chemicals and Nutrition & Health Solutions segments. Standalone net profit rose even more sharply by ~62% to Rs. 263.4 crore. EPS for the year stood at Rs. 15.89 (consolidated) and Rs. 16.54 (standalone). Record date for the dividend is July 25, 2025.
Strong profit growth despite flat revenue signals significant margin expansion and improved operating efficiency, which should be viewed positively by shareholders. The total dividend of Rs. 5 per share offers a reasonable payout alongside retained earnings growth, and the clean (unmodified) audit opinion adds confidence in the reported numbers.